Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inductively Coupled Plasma–Mass Spectrometry (ICP–MS): Overview

Inductively Coupled Plasma–Mass Spectrometry (ICP–MS): Overview

In inductively coupled plasma–mass spectrometry (ICP–MS), an inductively coupled plasma (ICP) torch is used as an atomizer and ionizer. Solid samples are dissolved and volatilized before being introduced into the high-temperature argon plasma, while solution samples are nebulized and passed through the high-temperature argon plasma. Plasma dissociates the analytes and ionizes their component atoms to form a mixture of positive ions and molecular species. The positive ions are then passed on to...

Inductively Coupled Plasma Atomic Emission Spectroscopy: Principle

Inductively Coupled Plasma Atomic Emission Spectroscopy: Principle

Inductively coupled plasma (ICP) is the most widely used plasma source in atomic emission spectroscopy (AES), also known as Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES). The ICP source, or torch, consists of three concentric quartz tubes with argon gas flowing through them. A spark from a Tesla coil initiates the ionization of argon, generating a high-temperature plasma.
The ions and electrons produced interact with the fluctuating magnetic field created by a water-cooled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evidence for coordinate CTCF and histone H3.3 activities in K27M diffuse midline gliomas.

Acta neuropathologica communications·2026

Same author

Ranking by engagement and non-engagement signals: Learnings from industry.

Annals of the New York Academy of Sciences·2025

Same author

Governing with public engagement: an anticipatory approach to human genome editing.

Science & public policy·2024

Same author

Noncanonical function of folate through folate receptor 1 during neural tube formation.

Nature communications·2024

Same author

Knockout tales: the versatile roles of histone H3.3 in development and disease.

Epigenetics & chromatin·2023

Same author

Non-canonical function of folate/folate receptor 1 during neural tube formation.

bioRxiv : the preprint server for biology·2023

Search research articles

Related Experiment Video

Updated: May 30, 2026

Generation of Mice Derived from Induced Pluripotent Stem Cells

Generation of Mice Derived from Induced Pluripotent Stem Cells

Published on: November 29, 2012

Inducing iPSCs to escape the dish.

Bonnie Barrilleaux¹, Paul S Knoepfler

¹Department of Cell Biology and Human Anatomy, University of California Davis School of Medicine, Sacramento, CA 95817, USA.

|August 6, 2011

Summary

Induced pluripotent stem cells (iPSCs) show promise for cell therapies but face challenges. Addressing immune rejection, genomic alterations, and clinical efficacy is crucial for FDA approval and therapeutic use.

Area of Science:

Stem cell biology
Regenerative medicine
Immunology

Background:

Induced pluripotent stem cells (iPSCs) offer potential for autologous cell therapies.
Significant hurdles impede the clinical translation of iPSCs.
Concerns exist regarding the immunogenicity and genomic stability of iPSCs.

Purpose of the Study:

To identify and discuss solutions for key challenges in iPSC clinical translation.
To provide a roadmap for advancing iPSC-based therapies.
To address FDA requirements for efficacy and safety evaluation.

Main Methods:

Review of recent literature on iPSC transplantation and immunogenicity.
Analysis of genomic and epigenomic alterations during reprogramming.

More Related Videos

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Published on: April 7, 2008

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Published on: November 8, 2017

Related Experiment Videos

Last Updated: May 30, 2026

Generation of Mice Derived from Induced Pluripotent Stem Cells

Generation of Mice Derived from Induced Pluripotent Stem Cells

Published on: November 29, 2012

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Generating iPS Cells from MEFS through Forced Expression of Sox-2, Oct-4, c-Myc, and Klf4

Published on: April 7, 2008

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Published on: November 8, 2017

Evaluation of iPSC efficacy and tumorigenicity in preclinical models.

Main Results:

Recent studies indicate potential immune rejection of iPSC-derived teratomas in syngeneic hosts.
Reprogramming can induce genomic and epigenomic changes with unknown clinical relevance.
Limited data exists on iPSC efficacy and tumorigenicity in clinically relevant transplantation models.

Conclusions:

Overcoming challenges in immunogenicity, genomic stability, and clinical validation is essential for iPSC therapy.
Further research is needed to ensure the safety and efficacy of iPSCs for therapeutic applications.
A strategic roadmap is required to facilitate the clinical translation of iPSC technology.